aTyr Pharma, a privately held San Diego-based biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for human therapeutics, announced the closing of its $10.5 million round of Series B financing.
Co-led by San Francisco-based Alta Partners and Boston-based Polaris Venture Partners, the financing also included Imagene and Cardinal Partners, aTyr’s founding institutional investor.
David Mack, Ph.D., director at Alta Partners and Amir Nashat, Ph.D., partner at Polaris Venture Partners, joined aTyr’s board of directors in connection with the financing. The capital is supporting internal research and development efforts, as well as expanding the company’s management and operations.
Founded by Paul Schimmel Ph.D., professor at The Scripps Research Institute, John Clarke of Cardinal Partners, and colleagues, aTyr is targeting a family of cellular proteins that have demonstrated therapeutic potential.
“aTyr presents a rich opportunity to identify and develop new protein biologics with the potential to address numerous pathogenic processes,” said Dr. Schimmel. “I am pleased to have such a strong and familiar investor syndicate in Alta Partners, Cardinal Health Partners and Polaris – three firms that have built successful companies with me in the past, and to be able to work with Joon Kim, CEO of Imagene and Sunghoon Kim, Professor at Seoul National University.”
Since the closing of the Series B financing the company has established operations in San Diego and has hired Christina Waters, Ph.D., as president and COO.